Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.37 |
| ▸ | MELK | Q14680 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 3/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 3/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6336693 | 0.90 | EGFR (0.39) | IRAK4EHMT2MELKEGFRERBB2 | |
| SCHEMBL6344434 | 0.84 | SRC (0.42) | EHMT2EGFRERBB2 | |
| SCHEMBL6337395 | 0.83 | KDM4E (0.45) | IRAK4EHMT2MELK | |
| SCHEMBL6336432 | 0.79 | EHMT2 (0.39) | EHMT2EGFRERBB2SYK | |
| SCHEMBL6343097 | 0.79 | ACP1 (0.42) | IRAK4EHMT2 | |
| SCHEMBL6338531 | 0.77 | SRC (0.42) | EHMT2EGFRERBB2 | |
| SCHEMBL6143695 | 0.75 | EGFR (0.53) | EGFRERBB2NUDT1 | |
| SCHEMBL6336773 | 0.72 | KDM4E (0.40) | — | |
| SCHEMBL6334461 | 0.71 | PDGFRB (0.59) | — | |
| SCHEMBL6592750 | 0.71 | DPP4 (0.42) | IRAK4EHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960580-B2 | Nitrogenous heterocyclic substituted quinoline compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1490362-A2 | (HOMO)PIPERAZINE SUBSTITUTED QUINOLINES FOR INHIBITING THE PHOSPHORYLATION OF KINASES | Millennium Pharmaceuticals, Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20030004158-A1 | Nitrogen containing heterocyclic quinoline compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| WO-2002072578-A2 | (HOMO) PIPERAZINE SUBSTITUTED QUINOLINES FOR INHIBITING THE PHOSPHORYLATION OF KINASES | MILLENNIUM PHARMACEUTICALS (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004158-A1 | Nitrogen containing heterocyclic quinoline compounds | WNK2, PDGFA, PDGFRA | IRAK4 2268/4885EHMT2 4072/4885MELK 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.